DNAJC13 Gene PARK21 Parkinson NGS Genetic Test
Short Name: PARK21 NGS Genetic Test
Also known as: DNAJC13 Gene Mutation Analysis, PARK21 Genetic Test, DNAJC13 NGS Sequencing, RME-8 Gene Parkinson Test, Early-Onset Parkinson Genetic Panel
DNAJC13 Gene PARK21 Parkinson NGS Genetic Test test available at DNA Labs India for ₹20,000. Uses Next Generation Sequencing (NGS), Sanger Sequencing (confirmation if required), Bioinformatic Variant Analysis on Blood or Extracted DNA or One drop Blood on FTA Card samples. Results in Results are typically available within 3 to 4 weeks from the date of sample receipt at the laboratory. Urgent processing may be available upon request—contact DNA Labs India for expedited turnaround options.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr SULOCHANA HEMCHANDRA HOLLA
Consultant Medical Geneticist · Reg: 8532
Last reviewed: September 7, 2026
Overview
This test is performed to identify pathogenic or likely pathogenic mutations in the DNAJC13 gene that cause PARK21-associated Parkinson disease. The primary purpose is to establish a molecular diagnosis in symptomatic individuals, differentiate PARK21 from other genetic and idiopathic forms of Parkinson disease, guide treatment and management strategies, enable predictive testing in at-risk family members, and support genetic counselling. The test may also be ordered for research purposes and to assess eligibility for clinical trials involving gene-specific therapeutic interventions.
- Test Code
- 1781
- CPT Code
- 81479
- ICD Code
- G20
- Price
- ₹20,000
- Sample Type
- Blood or Extracted DNA or One drop Blood on FTA Card
- Result Time
- Results are typically available within 3 to 4 weeks from the date of sample receipt at the laboratory. Urgent processing may be available upon request—contact DNA Labs India for expedited turnaround options.
- Fasting Required
- No
- Method
- Next Generation Sequencing (NGS), Sanger Sequencing (confirmation if required), Bioinformatic Variant Analysis
Sample Collection
No special preparation such as fasting is required. A clinical history of the patient and a genetic counselling session to draw a pedigree chart of family members affected with PARK21 or other Parkinson disease subtypes is recommended prior to sample collection. Inform the laboratory of any recent blood transfusions.
Method: Venipuncture / FTA Card finger-prick
Laboratory Analysis
A trained phlebotomist will collect 3-5 mL of venous blood in an EDTA (lavender-top) vacutainer tube. Alternatively, a single drop of blood on an FTA card or previously extracted DNA may be submitted. The sample is labelled, sealed, and transported to the laboratory under ambient temperature conditions.
Report Delivery
After sample collection, patients may resume normal activities immediately. The DNA is extracted in the laboratory, and NGS library preparation and sequencing are performed. Genetic counselling is recommended upon receipt of results to ensure proper understanding and interpretation of findings.
Timeline: Results are typically available within 3 to 4 weeks from the date of sample receipt at the laboratory. Urgent processing may be available upon request—contact DNA Labs India for expedited turnaround options.
Patient Instructions
About This Test
Who Should Get This Test
This test is performed to identify pathogenic or likely pathogenic mutations in the DNAJC13 gene that cause PARK21-associated Parkinson disease. The primary purpose is to establish a molecular diagnosis in symptomatic individuals, differentiate PARK21 from other genetic and idiopathic forms of Parkinson disease, guide treatment and management strategies, enable predictive testing in at-risk family members, and support genetic counselling. The test may also be ordered for research purposes and to assess eligibility for clinical trials involving gene-specific therapeutic interventions.
How to Prepare
- Use a sterile EDTA (lavender-top) vacutainer tube for blood collection
- Ensure 3-5 mL of whole blood is collected via standard venipuncture technique
- Alternatively, a single drop of blood on an FTA card or extracted DNA can be submitted
- Label the sample clearly with patient name, date of birth, and unique ID
- Store and transport the sample at ambient room temperature (15-30°C)
- Do not freeze whole blood samples
- Ship the sample to DNA Labs India within 48 hours of collection
Doctor's Notes
Reviewed by Dr SULOCHANA HEMCHANDRA HOLLA — MBBS, MD (Medical Genetics) · Reg. No. 8532
"The DNAJC13 gene test is particularly valuable for patients presenting with early-onset Parkinson-like symptoms before age 50. Identifying a pathogenic variant in DNAJC13 can help confirm a diagnosis of PARK21, guide personalized treatment strategies, and enable cascade genetic testing for at-risk family members. I recommend this test for any patient with a suggestive family history or atypical presentation of Parkinsonism."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Clotted blood sample
- Sample collected in heparin tube instead of EDTA
- Haemolysed or severely degraded sample
- Incorrectly labelled or unlabelled sample
- Sample volume insufficient for DNA extraction
- Sample older than 7 days at ambient temperature for whole blood
Understanding Your Results
A negative result indicates that no known disease-causing mutations were identified in the DNAJC13 gene. This does not entirely exclude a genetic basis for the patient's symptoms, as mutations in other genes or undetectable variant types may be responsible. Clinical correlation and further genetic testing may be warranted.
Reduces the likelihood of PARK21 but does not confirm absence of Parkinson disease
A pathogenic variant in the DNAJC13 gene was identified, supporting a molecular diagnosis of PARK21 Parkinson disease. This finding is consistent with autosomal dominant inheritance, meaning each first-degree relative has a 50% chance of carrying the same variant. Cascade testing of at-risk family members is recommended.
Confirms genetic diagnosis of PARK21; enables personalised management, prognostic counselling, and family screening
A variant classified as likely pathogenic was identified. This strongly suggests a genetic basis for the patient's condition but may require additional evidence such as segregation analysis in affected family members or functional studies for definitive classification.
Highly suggestive of PARK21; follow-up genetic counselling and family studies recommended
A variant was identified that currently lacks sufficient evidence to classify it as pathogenic or benign. This result is not diagnostic and should not be used alone for clinical decision-making. Periodic reanalysis is recommended as new scientific data becomes available.
Inconclusive; clinical correlation and longitudinal follow-up required; reclassification may occur over time
A variant was identified that is considered unlikely to be disease-causing based on current evidence. These variants are typically common in the general population and are not associated with PARK21.
Not clinically significant for PARK21 diagnosis
Consult a neurologist or movement disorder specialist if you experience tremors, muscle stiffness, slowed movement, balance problems, cognitive decline, or psychiatric symptoms—especially if onset occurs before age 50 or there is a family history of Parkinson disease. Seek immediate genetic counselling if this test returns a positive or uncertain result. A referral to a clinical geneticist is recommended for comprehensive family evaluation and cascade testing of at-risk relatives.
Limitations
- ⚠This test is limited to the DNAJC13 gene only and does not screen other Parkinson disease-associated genes unless specifically ordered as part of a broader panel
- ⚠Variants of Uncertain Significance (VUS) may be detected that cannot be definitively classified as pathogenic or benign at the time of reporting
- ⚠Deep intronic mutations, regulatory region variants, and large structural rearrangements beyond the detection capability of the NGS platform may not be identified
- ⚠A negative result does not exclude the possibility of Parkinson disease caused by mutations in other genes or non-genetic factors
- ⚠Mosaicism at low allele frequencies may not be reliably detected
- ⚠Test results should always be interpreted in conjunction with clinical findings, family history, and neurological evaluation by a qualified specialist
Risks & Considerations
- ●Minor bruising or discomfort at the blood draw site
- ●Very small risk of infection at the venipuncture site
- ●Potential psychological impact of receiving genetic test results, particularly positive or uncertain findings
- ●Risk of insurance or employment discrimination based on genetic information (protected under applicable laws)
- ●Possible identification of Variants of Uncertain Significance that may cause anxiety without providing definitive answers
Interfering Factors
- ●Degraded or low-quality DNA due to improper sample storage or transport
- ●Recent blood transfusion within the past 4 weeks may affect DNA analysis
- ●Heparinised blood samples (EDTA tubes are preferred)
- ●Contamination during sample collection or processing
- ●Insufficient sample volume leading to inadequate DNA yield
Compare With Similar Tests
| Test | DNAJC13 Gene PARK21 Parkinson NGS Genetic Test | LRRK2 Gene Parkinson NGS Test | Parkin (PARK2) Gene Deletion/Duplication Test | SNCA Gene (PARK1/PARK4) NGS Test | Comprehensive Parkinson Disease Gene Panel |
|---|---|---|---|---|---|
| Comparison | DNAJC13 Gene PARK21 Parkinson NGS Genetic Test |
Frequently Asked Questions
What is the DNAJC13 Gene PARK21 Parkinson NGS Genetic Test?
Who should get this DNAJC13 gene test?
What is PARK21 Parkinson disease?
What sample is required for this test?
How much does the DNAJC13 Gene PARK21 NGS Genetic Test cost?
How long does it take to get the results?
Is home sample collection available for this test?
What does a positive result mean?
What does a negative result mean?
Can this test detect all types of mutations in the DNAJC13 gene?
Is genetic counselling required before taking this test?
Is this test covered by health insurance in India?
Related Tests
Angelman Syndrome Test
₹10,000Duchenne / Becker Muscular Dystrophy (DMD / BMD) Gene Mutation Test
₹14,000Episodic Ataxia Type 1 Hotspot Test
₹11,500Episodic Ataxia Comprehensive Profile Hotspot Test
₹16,000Megalencephalic Leukoencephalopathy with Subcortical Cysts Van Der Knaap and Nalband MLC Gene Hotspot Mutation Test
₹7,500Analyzer 18 SMA 18 Test Panel
₹1,755Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.